FDA accepts Karyopharm sNDA for selinexor in myelofibrosis
The FDA has accepted Karyopharm Therapeutics’ application for selinexor plus ruxolitinib in myelofibrosis, with a regulatory decision expected by June 2027.
The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Karyopharm’s selinexor in combination with ruxolitinib for adults with myelofibrosis.
The application is primarily supported by results from the Phase 3 SENTRY trial, which evaluated the combination in patients who had not previously received a Janus kinase (JAK) inhibitor. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 28 June 2027.
If approved, the combination could become the first approved combination therapy for myelofibrosis, according to Karyopharm. Selinexor is already marketed as XPOVIO in the US for certain multiple myeloma indications.
Phase 3 SENTRY trial supports regulatory application
SENTRY, also known as XPORT-MF-034, enrolled 353 patients with myelofibrosis who had not previously received a JAK inhibitor and had platelet counts above 100 × 10⁹/L.
Participants were randomised in a 2:1 ratio to receive either once-weekly selinexor at a dose of 60mg alongside ruxolitinib, or placebo alongside ruxolitinib.
The study had two co-primary endpoints: the proportion of patients achieving at least a 35% reduction in spleen volume at week 24, and the average change in absolute total symptom score over 24 weeks compared with baseline.
Spleen enlargement and symptoms such as fatigue, abdominal discomfort, night sweats and bone pain can have a substantial impact on people living with myelofibrosis.
The trial’s results were presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in the Journal of Clinical Oncology. Further results were presented at the 2026 European Hematology Association Congress, where the presentation was recognised among the meeting’s six best abstracts.
However, Karyopharm’s latest announcement does not include the numerical efficacy or safety findings from SENTRY. The application acceptance confirms that the FDA will review the submission, rather than establishing that the combination has demonstrated a particular level of clinical benefit.
Selinexor could expand treatment options
Myelofibrosis is a rare blood cancer in which scar tissue builds up in the bone marrow, disrupting the production of healthy blood cells. The disease can cause anaemia, an enlarged spleen and progressive symptoms including fatigue and weakness.
Karyopharm estimates that approximately 20,000 people in the US and 19,000 in the European Union have the condition.
JAK inhibitors, including ruxolitinib, are an established treatment class for myelofibrosis. The company is investigating whether adding selinexor could improve outcomes compared with ruxolitinib alone.
Selinexor is an oral inhibitor of exportin 1 (XPO1), a nuclear export protein involved in transporting proteins and other molecules out of the cell nucleus. By inhibiting XPO1, the drug is designed to alter the activity of tumour-suppressing proteins and other cellular processes involved in cancer development.
Richard Paulson, president and CEO of Karyopharm, said: “FDA acceptance of our sNDA is a significant milestone in the development of selinexor for patients with myelofibrosis and marks an important step toward expanding selinexor’s impact and reach.”
FDA review expected to conclude in June 2027
Karyopharm said its teams are preparing for a potential launch while the application undergoes regulatory review.
Reshma Rangwala, chief medical officer and head of research at Karyopharm, said: “Selinexor offers a differentiated mechanism of action and, if approved, selinexor plus ruxolitinib could become the first approved combination therapy for patients with myelofibrosis.”
The FDA’s target action date of 28 June 2027 gives the company a defined regulatory milestone, although the final decision will depend on the agency’s review of the submitted evidence.
For now, the combination remains investigational in myelofibrosis. An approval would extend selinexor’s use into another blood cancer indication and potentially provide an additional treatment option for patients starting therapy.




